Clinical Trial

Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients

Study acronym: MagSnow2
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 26, 2024 (before its estimated July 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
The overall aim is to demonstrate that the use of superparamagnetic iron oxide nanoparticles (SPIO) as a tracer in an ultra-low dose (0.1 ml) is non-inferior for sentinel lymph node (SLN) detection in patients with breast cancer compared to the dual technique using Tc99m +/- blue dye, and to evaluate MRI breast artefacts and skin staining over time.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-10.
Trial Details
NCT Number NCT06169072
Lead Sponsor Vastra Gotaland Region
Conditions Breast Cancer, Sentinel Lymph Node
Enrollment 220 participants
Start Date 2023-01-01
Primary Completion 2024-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2024-01-26